CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 563 enrolled
Drug / intervention
Indacaterol 150 µg +2 moredrug
Likely dose
Indacaterol 150 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00792805
NCT00792805Phase 3Completed
CompareCT.gov

A Phase III, 26-week Multicenter Randomized Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (150 and 300 µg Once Daily [od]) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Novartis Pharmaceuticals·interventional·Posted Nov 18, 2008·Updated Aug 17, 2011

In Brief

A Phase 3 clinical trial evaluating Indacaterol 150 µg, Indacaterol 300 μg, and 1 other intervention for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 563 participants across 15 sites in 3 countries.

Detailed Summary

This study evaluated the efficacy and safety of two doses of indacaterol in adults aged 40 or over with chronic obstructive pulmonary disease (COPD) in China and in two other countries.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease (COPD)
CountriesAustralia, China, India
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 18, 2008
Enrollment StartNov 1, 2008
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.6 years ago

Interventions

Indacaterol 150 µgdrug

Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).

Indacaterol 300 μgdrug

Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).

Placebo to indacateroldrug

Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).